What baseline laboratory tests and monitoring schedule are required for leflunomide therapy?

Leflunomide Laboratory Monitoring Requirements

For leflunomide therapy, obtain baseline complete blood count (CBC), liver transaminases (ALT/AST), and creatinine, then monitor ALT monthly for the first 6 months, followed by every 6-8 weeks thereafter; CBC should be monitored monthly for 6 months, then every 6-8 weeks, with blood pressure checks at each visit 1, 2.

Baseline Testing (Before Starting Leflunomide)

Before initiating leflunomide, you must obtain:

• Complete blood count (CBC with differential, platelets, hemoglobin/hematocrit)
• Liver function tests (ALT/SGPT at minimum, AST recommended)
• Serum creatinine
• Pregnancy test (mandatory in all women of childbearing potential) 2
• Tuberculosis screening (tuberculin skin test or IGRA) 2
• Hepatitis B and C screening (leflunomide is not recommended if positive) 2

Ongoing Monitoring Schedule

First 6 Months (Intensive Phase)

• ALT (SGPT): Monthly 1, 2
• CBC (platelets, WBC, hemoglobin/hematocrit): Monthly 2
• Blood pressure: At each visit 2
• Monitoring interval: Every 2-4 weeks 1

After 6 Months (Maintenance Phase)

Once stable:

• ALT: Every 6-8 weeks (or every 8-12 weeks per ACR guidelines) 1
• CBC: Every 6-8 weeks 2
• Blood pressure: Periodically 2
• Monitoring interval: Every 8-12 weeks 1

Critical Action Thresholds for ALT Elevations

The FDA label provides specific guidance 2:

• ALT 2-3× ULN (confirmed): Reduce dose to 10 mg daily and monitor closely. May continue if levels stabilize.
• ALT >3× ULN: Immediately discontinue leflunomide and initiate drug elimination procedure with cholestyramine 8 grams three times daily for 11 days 2
• Recheck ALT levels and consider retreatment with cholestyramine if needed

Special Monitoring Situations

Combination with Methotrexate

If leflunomide is combined with methotrexate (increasingly common in clinical practice):

• Monthly monitoring indefinitely for ALT, AST, and serum albumin 2
• Follow ACR methotrexate liver toxicity monitoring guidelines
• Higher risk of 2-3× ALT elevations (occurred in 5 of 30 patients in combination studies) 2
• Research shows 13-20% develop elevated transaminases with combination therapy 3

Patients with Risk Factors for Hepatotoxicity

More frequent monitoring is warranted for patients with 1:

• Pre-existing liver disease
• Concomitant hepatotoxic medications
• Alcohol use
• Multiple DMARD therapy
• Abnormal baseline laboratory values

Common Pitfalls to Avoid

1. Don't skip baseline hepatitis screening: Leflunomide is contraindicated in hepatitis B or C due to severe hepatotoxicity risk 2

2. Don't forget pregnancy prevention: Leflunomide is highly teratogenic. Women of childbearing potential require reliable contraception and monthly pregnancy testing should be considered 2

3. Don't delay drug elimination for significant ALT elevations: Rare fatal hepatotoxicity cases have occurred, mostly within 6 months 2. Act quickly with cholestyramine washout.

4. Don't ignore hematologic monitoring: Rare but serious pancytopenia, agranulocytosis, and thrombocytopenia can occur, especially with concomitant immunosuppressants 2

5. Monitor blood pressure: Hypertension occurs in >5% of patients and requires regular screening 2

The 2016 ACR guideline explicitly provides this monitoring schedule in tabular format, making it the authoritative reference for U.S. practice 1. The FDA label reinforces these requirements with additional safety warnings about hepatotoxicity and bone marrow suppression 2.